Proactive Investors - Run By Investors For Investors

Enzo Biochem’s $22 million in fiscal 3Q net income includes $29 million stemming from legal settlement

Cash and cash equivalents were $64 million and working capital $71 million
bio
Enzo researches, develops, manufactures, and markets diagnostic and research products

Enzo Biochem Inc (NYSE:ENZ) reported fiscal third-quarter net income of $22.3 million, which included nearly $29 million in cash stemming from an intellectual property settlement.

On a per-share basis, the New York-based company earned $0.47 per share, compared to a net loss of $3 million, or $0.06 per share, in the year-ago quarter.

Enzo said revenue for the quarter, which ended April 30, was $19.7 million – an increase of 2% from the prior-year quarter.

Cash and cash equivalents at the end of the quarter were $64 million and working capital was $71 million, the company said.

Three-pronged strategy

Enzo also announced three-pronged short-term value creation and growth strategy, which includes strategic relationships with leading global life sciences and medical device companies, building a new model for the diagnostic marketplace and returning to operating profitability and growth in the lab segment.

“Enzo is poised to leverage and capitalize on our deep-rooted, proprietary technology, product development and intellectual property portfolio in very real, short-term strategic initiatives designed to unlock the value we know exists across our business,” said CEO Elazar Rabbani.

Enzo researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

View full ENZ profile View Profile

Enzo Biochem Timeline

Related Articles

Weight loss
January 07 2019
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product
microscope
April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone
PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use